Sanofi Sa · EURONEXT:SAN
Sanofi Sa — Deutsche Bank Healthcare Conference 2015
22 slides from Sanofi Sa's conference presentation, May 6, 2015
Slide 1: Deutsche Bank Healthcare Conference
Deutsche Bank Healthcare Conference Jérôme Contamine, Executive Vice President, Chief Financial Officer Boston – May 6, 2015
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their under
Slide 3: Q1 2015 - A Good Start to the Year
Q1 2015 - A Good Start to the Year ● Sales up +2.4% despite lower vaccines and U.S. Lantus® Delivering sales(1) 1 top line growth ● Solid performance of Genzyme and Merial Posting ● Higher OpEx driven by new launches 2 strong financial ● Business EPS up +2.6% at CER(2) results Bringing innovative ●
Slide 4: Solid Sales and Business EPS Delivered in Q1 2015
Solid Sales and Business EPS Delivered in Q1 2015 Net Sales Business EPS €8,810m €1.32 +€0.12 +€782m +€0.03 +€186m +2.4% +2.6% €1.17 at CER(1) at CER(1) €7,842m Q1 2014 Incremental FX Impact Q1 2015 Q1 2014 Incremental FX Impact Q1 2015 Sales at CER EPS at CER (1) On a reported basis, Q1 2015 sales
Slide 5: Strong FX Tailwind on Top and Bottom Line
Strong FX Tailwind on Top and Bottom Line in Q1 2015 as the U.S. Dollar Strengthened Quarterly Currency Impact Net Sales(1) Business EPS +9.9% +10.2% +€782m +€0.12 +2.7% +€229m +1.5% Q1 2014 Q2 2014 Q3 2014 Q1 2014 Q2 2014 Q3 2014 +€0.02 -€81m Q4 2014 Q1 2015 Q4 2014 Q1 2015 -1.0% -€0.03 -2.2% -€443
Slide 6: Balanced Geographical Sales Split with Solid Growth in Emerging Markets
Balanced Geographical Sales Split in Q1 2015 with Solid Growth in Emerging Markets Q1 2015 Sales by Geographies (in €m) RoW (2) Emerging Markets Total Sales by Region Western EU €944m €2,031m -3.5% at CER €846m €849m +0.6% at CER 10.6% 23.1% €586m Emerging €530m Markets (1) 32.5% €2,859m +7.3% at CE
Slide 7: Sales Growth Driven by Genzyme and Merial
Sales Growth Driven by Genzyme and Merial in Q1 2015(1) % of Sales Q1 2015 Sales by Business Areas Growth at CER 84.6% Pharmaceuticals €7,455m +2.2% 20.9% Diabetes €1,837m -3.2% 11.1% Consumer Healthcare €979m +5.3% 9.3% Genzyme €821m +30.9% 5.4% Generics €478m +10.2% 4.1% Oncology €357m -7.3% 33.8%
Slide 8: Genzyme Rare Disease Products Delivered Double-Digit Growth
Genzyme Rare Disease Products Delivered Double-Digit Growth in Q1 2015 ● Rare Disease sales reached €613m in Top 3 Rare Disease Sales (€m) Q1 2015, up 15.9% €199m +10.1% ● Sustained leadership positions(1) €156m at CER €141m in Gaucher, Fabry and Pompe diseases +19.0% +27.6% at CER ● Gaucher disease
Slide 9: Genzyme's Multiple Sclerosis Business Continued to Accelerate
Genzyme’s Multiple Sclerosis Business Continued to Accelerate in Q1 2015 Genzyme MS Franchise Sales (€m) ● MS sales up +118% at CER to €208m in €208m Q1 2015 ● Aubagio® sales of €170m more than doubled vs. €78m in Q1 last year ● Only oral treatment with sustained accumulation of disability data in U
Slide 10: Merial Started 2015 with Strong Growth Driven by NexGard and Frontline
Merial Started 2015 with Strong Growth Driven by NexGard® Launch and Frontline® Stabilization Merial Sales Growth at CER ● Q1 2015 sales of €658m up +13.5% +13.5% +12.7% ● Companion animal sales up +13.1% to +11.5% €443m (67% of sales) ● Production animal sales up +14.5% to +6.2% €215m ● NexGard® sa
Slide 11: Sanofi Pasteur Sales Reflect the Delay of the Southern Hemisphere Influenza Campaign
Sanofi Pasteur Sales in Q1 2015 Reflect the Delay of the Southern Hemisphere Influenza Campaign ● Q1 2015 Sanofi Pasteur sales were Vaccine Sales (€m) €697m, down 4.6% at CER €697m ● Excluding influenza vaccines, sales grew €628m 17.2% in Q1 -4.6% at CER ● Strong PPH sales of €282m, +15.6% were driv
Slide 12: Diabetes Sales Reflect Expected Change in U.S. Lantus Net Pricing
Diabetes Sales Reflect Expected Change in U.S. Lantus® Net Pricing ● Global diabetes sales of €1,837m Diabetes Sales (€m) down -3.2% at CER(1) in Q1 2015 €1,837m ● In Emerging Markets and Western EU, €1,662m diabetes sales were up +18.5% and +4.7%, respectively ● U.S. Lantus® sales were down 13.1% d
Slide 13: Global Launch of a New Once-Daily Long-Acting Basal Insulin Underway
Global Launch of a New Once-Daily Long-Acting Basal Insulin Underway ● Toujeo® was launched in the U.S. at the end of March ● Secured earlier and broader market access than expected ● Toujeo® COACH patient support program available at launch ● European Commission approved Toujeo® in April 2015 ● Lau
Slide 14: Sanofi Expects to Launch High Potential New Medicines and Vaccines at an Accelerated Pace
Sanofi Expects to Launch High Potential New Medicines and Vaccines at an Accelerated Pace ILLUSTRATIVE Up to 18 Launches 2014 - 2020 Dengue PR5i Shan5 ® Vaccine Vaccine (U.S.) insulin patisiran Anti-CD38 Rotavirus sarilumab Vaccine (U.S.) lispro mAb Vaccine Praluent™ is the intended trade name for a
Slide 15: Regulatory Filings for Three Major New Medicines or Vaccines Submitted over the Last Year
Regulatory Filings for Three Major New Medicines or Vaccines Submitted over the Last Year Key Regulatory Filings Hypercholesterolemia Pediatric hexavalent vaccine Dengue PR5i 6-in-1 Dengue vaccine U.S. U.S. Endemic markets(1) E.U. Praluent® (alirocumab) is developed in collaboration with Regeneron (
Slide 16: Praluent Has the Potential to Transform Management of Hypercholesterolemic Patients
Praluent® Has the Potential to Transform Management of Hypercholesterolemic Patients with High CV Risk ● Regulatory reviews underway in the U.S. and Europe ● FDA decision expected in July 2015(1) ● EU decision expected in Q1 2016 ● 18-month results of ODYSSEY LONG TERM study were published in NEJM(2
Slide 17: On Track to Make Dengue the Next Vaccine-Preventable Disease
On Track to Make Dengue the Next Vaccine-Preventable Disease A Breakthrough Innovation to Help Reduce the Burden of Dengue(1) ● Rolling submission for Dengue vaccine initiated in endemic countries in Asia and Latin America ● First completed submission expected in H1 2015 ● First commercial batches p
Slide 18: Additional Clinical Milestones and Regulatory Filings Expected in 2015
Additional Clinical Milestones and Regulatory Filings Expected in 2015 Key Milestones in 2015 sarilumab (2) Type 2 Diabetes Type 2 Diabetes Rheumatoid Arthritis ELIXA study results Completion of two Further Phase III data support U.S. regulatory Phase III trials expected in 2015 submission expected
Slide 19: Innovation Momentum Set to Continue in 2015
Innovation Momentum Set to Continue in 2015 2015 Expected Regulatory Decisions Q1 Q2 Q3 Q4 ● Toujeo® in Diabetes in U.S. & EU ● Praluent® (alirocumab) in Hypercholesterolemia (U.S.) ● PR5i 6-in-1 pediatric vaccine (U.S.) ● Dengue vaccine in Endemic Countries Expected Regulatory Submissions Q1
Slide 20: Net Debt Increased by 5.6% due to Translation Impact of Debt Held in U.S. Dollars
Net Debt Increased by 5.6% in Q1 2015 due to Translation Impact of our Debt Held in U.S. Dollars Net Debt (in €m) -€773m FCF -€327m €7,171m €1,602m €1,247m €7,571m -€794m -€355m €247m Net Debt (1) Net Cash from CapEx Proceeds from Share Repurchase Acquisitions, Other (3) Net Debt (1) Mar 31, 2014 Op
Slide 21: Outlook for 2015 - Investing in Future Growth Drivers
Outlook for 2015 - Investing in Future Growth Drivers FY 2015 Business EPS Growth Stable to slightly growing at CER(1) FX impact on Business EPS Approximately +12%(2) (1) FY 2014 Business EPS of €5.20 (2) Difference between variation on a reported basis and variation at CER, when applying March 2015
Slide 22: Our Focus Continues to Be on Excellence in Execution of Sanofi's Strategy
Our Focus Continues to Be on Excellence in Execution of Sanofi’s Strategy Strategy 2015 Focus Grow a global healthcare leader 1 with synergistic platforms Sustain leadership positions Bring innovative products 2 to market Ensure successful launches Adapt structure for future Focus company resources